

**MIR-007 ANGIOGENESIS MODULATORS
A MARKET INSIGHT REPORT– JULY 2010
CONTENTS**

I. SCOPE AND METHODOLOGY

II. REPORT SYNOPSIS

1. Introduction

Angiogenesis

Segmentation of Angiogenesis

Exhibit 1: Segmentation of Global Angiogenesis Therapeutic Products Market by Angiogenesis Modulators (Inhibitors and Stimulators) and Therapeutic Areas (Cancer, Cardiovascular and Other)

2. Global Market Analysis

Exhibit 2: Angiogenesis Therapeutic Products (2005-2012) – Global Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

3. Angiogenesis Modulators Analysis by Geographic Region

Inhibitors

Exhibit 3: Angiogenesis Inhibitors (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million (*Graphical Representation Included*).

Exhibit 4: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (*Graphical Representation Included*)

Exhibit 5: Angiogenesis Inhibitors (2005-2012) - Global Analysis (Current & Future) of Patients Treated by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in Million (*Graphical Representation Included*)

Exhibit 6: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Patients Treated Globally by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (*Graphical Representation Included*)

Stimulators

Exhibit 7: Angiogenesis Stimulators (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million (*Graphical Representation Included*).

Exhibit 8: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World.

Analysis of Angiogenesis Disease Area by Geographic Region

Cancer

Exhibit 9: Angiogenesis Therapeutic Products for Cancer (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million

Exhibit 10: Angiogenesis Therapeutic Products for Cancer (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World

Cardiovascular

Exhibit 11: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million

Exhibit 12: Angiogenesis Therapeutic Products for Cardiovascular Diseases (2006,

2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World.

Other

Exhibit 13: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million (*Graphical Representation Included*)

Exhibit 14: Angiogenesis Therapeutic Products for Other Angiogenesis Based Diseases (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World

Exhibit 15: List of Major Global Companies.

4. Regional Market Analysis

The United States

Exhibit 16: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

Major Companies in the United States

Abbott Laboratories

Adnexus Therapeutics, Inc.

Alcon, Inc.

Amgen, Inc.

Ångstrom Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc.

Cardium Therapeutics, Inc.

Celgene Corporation.

Collagenex Pharmaceuticals, Inc.

Eisai, Inc.

Entremed, Inc.

Genaera Corporation

Genentech, Inc.

Genvec, Inc.

Genzyme Corporation

Human Genome Sciences, Inc.

Imclone Systems, Inc.

Intradigm Corporation

Merck & Co., Inc. (USA)

OSI Pharmaceuticals, Inc.

Oxigene, Inc.

Pfizer, Inc.

The US Market Analysis by Type of Angiogenesis Modulators

Exhibit 17: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 18: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*).

Europe

Exhibit 19: Angiogenesis Therapeutic Products (2005-2012) – European Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*).

Major Companies in Europe

Antisoma plc (UK)

Astrazeneca plc (UK)

Bayer Healthcare AG (Germany)
F.Hoffmann-La Roche Ltd. (Switzerland)
Merck KGaA(Germany)
Novartis AG (Switzerland)
UCB SA (Belgium)

Angiogenesis Modulators Analysis by Geographic Region

Inhibitors

Exhibit 20: Angiogenesis Inhibitors (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US\$ Million (*Graphical Representation Included*)

Exhibit 21: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe (*Graphical Representation Included*)

Stimulators

Exhibit 22: Angiogenesis Stimulators (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe in US\$ Million (*Graphical Representation Included*)

Exhibit 23: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France, Switzerland and Rest of Europe

Asia-Pacific

Exhibit 24: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*).

Major Companies in Asia-Pacific
Bionomics Ltd. (Australia)
Chugai Pharmaceutical Co., Ltd. (Japan)
Progen Industries Ltd. (Australia)

Angiogenesis Modulators Analysis by Geographic Region

Inhibitors

Exhibit 25: Angiogenesis Inhibitors (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US\$ Million (*Graphical epresentation Included*)

Exhibit 26: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (*Graphical Representation Included*)

Stimulators

Exhibit 27: Angiogenesis Stimulators (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US\$ Million (*Graphical Representation Included*)

Exhibit 28: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (*Graphical Representation Included*)

Rest of World

Exhibit 29: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

Angiogenesis Modulators Analysis by Geographic Region

Inhibitors

Exhibit 30: Angiogenesis Inhibitors (2005-2012) – Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other^ in US\$ Million (*Graphical Representation Included*)

Exhibit 31: Angiogenesis Inhibitors (2006, 2009 and 2012) – Percentage Breakdown of

Rest of World Market Value by Geographic Region for Latin America and Other
(*Graphical Representation Included*).

Stimulators

Exhibit 32: Angiogenesis Stimulators (2005-2012) – Rest of World Market Analysis
(Current & Future) by Geographic Region for Latin America and Other[^]
in US\$ Million (*Graphical Representation Included*)

Exhibit 33: Angiogenesis Stimulators (2006, 2009 and 2012) – Percentage Breakdown of
Rest of World Market Value by Geographic Region for Latin America and
Other (*Graphical Representation Included*)

III. PRODUCT RESEARCH

1. Introduction

Angiogenesis – The Growth of New Blood Vessels

Global Growth Trends – Angiogenesis Therapeutic Products

Exhibit 34 Global Market for Angiogenesis Therapeutic Products: Geographic Regions
(Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through
2012 (*Graphical Representation Included*)

The Process

The Types

Sprouting Angiogenesis

Role of Angioproten in Sprouting of Angiogenesis

Intussusceptive Angiogenesis

Role of Intussusceptive Angiogenesis in Embryonic Vascular Network Configuration

Therapeutic Angiogenesis

Role of Therapeutic Angiogenesis in Various Diseases

Delivery of Drugs in Cancer Therapy through Angiogenesis

Angiogenic Therapy for Heart?

2. Modulators of Angiogenesis

Growth Trends – Global Angiogenesis Therapeutic Products by Modulators

Exhibit 35 Global Market for Angiogenesis Therapeutic Products: Angiogenesis Modulators
(Stimulators and Inhibitors) Ranked by Projected CAGR for 2005 through
2012 (*Graphical Representation Included*)

2.1 Angiogenesis Inhibitors

Growth Trends – Global Market for Angiogenesis Inhibitors

Exhibit 36 Global Market for Angiogenesis Inhibitors: Geographic Regions (Asia-Pacific,
United States, Europe) Ranked by Projected CAGR for 2005 through
2012 (*Graphical Representation Included*)

Natural Angiogenesis Inhibitors

Angiostatin – A Potent Angiogenesis Inhibitor of Tumor Growth

Heparin Hexasaccharide Fragment

Interleukin-12

Placental Ribonuclease Inhibitor

Retinoids

Thrombospondin-1 (TSP-1)

Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic Cell Activation

Cartilage Derived Inhibitor

Angioarrestin

Endostatin

Platelet Factor-4

Metalloproteinase Inhibitors

Interferon Alpha/Beta/Gamma
Other

2.2 Angiogenesis Stimulators

Growth Trends – Global Market for Angiogenesis Stimulators

Exhibit 37 Global Market for Angiogenesis Stimulators: Geographic Regions (Asia-Pacific, United States and Europe) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation Included*)

Natural Angiogenic Stimulators

Vascular Endothelial Growth Factor

VEGF Splice Variants and Their Functions

Role of VEGF in Various Diseases

Effect of VEGF & bFGF on In-vivo and In-vitro Conditions

Fibroblast Growth Factors

Basic FGF

Expression of bFGF (FGF2) in Various Diseases

Alzheimer's

Precursor Neural Cells of Mice

Acidic FGF

Role of aFGF in ADPKD

Expression of aFGF in Alzheimer's

Granulocyte Colony-Stimulating Factor

Impact of G-CSF on Neutrophils

The Usage of G-CSF in Pharma Industry

Angiogenin

Angiopoietin-1

Platelet Derived Endothelial Cell Growth Factor.

Uterine Cervical Cancers and Role of PD-ECGF

Leptin

Leptin's MoA

Midkine

Placental Growth Factor

Stimulation of Inflammation and Swelling – A Role of Placental Growth Factor

Hepatocyte Growth Factor (HGF)/Scatter Factor (SF)

Transforming Growth Factor (TGF)

TGF α

TGF β

The TGF β receptor

Other

3. Angiogenesis in Diseases

Growth Trends – Global Market for Angiogenesis Therapeutic Areas

Exhibit 38 Global Market for Angiogenesis Therapeutic Products: Major Angiogenesis Therapeutic Areas (Cardiovascular Disorders, Other* and Cancer) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation Included*)

3.1 Remedy of Diseases with Angiogenesis Inhibitors

Angiogenesis Inhibitors-Patient Demographics

Exhibit 39 Angiogenesis Inhibitors (2005-2012): Global Analysis (Current & Future) of Patients Treated in Million

Cancer Therapy – Role of Angiogenesis

Global Market for Major Cancer Types

Exhibit 40 Major Cancer Types (2005 & 2006): Global Market for Major Cancer Types – Breast, Colorectal, Lung and Prostate in US\$ Million (*Graphical Representation Included*)

Growth Trends – Global Market for Angiogenesis Therapeutic Products for Cancer

Exhibit 41: Global Market for Angiogenesis Therapeutic Products for Cancer: Geographic Regions (Asia-Pacific, United States

and Europe) Ranked by Projected CAGR
for 2005 through 2012 (*Graphical Representation Included*)
Cancer Therapy Angiogenesis Vs Conventional
Conventional Cancer Treatments
Surgery
Radiation Therapy for Healing Cancer
Chemotherapy Treatment
Hormone Stimulation Therapy
Process of Immuno Therapy
Experimenting Phase
Targeted Therapy
Angiostatic Therapy
Angiostatic Agents
Angiolytic Photodynamic Therapy
Researches in Development of Cancer Therapy
Angiobalans
Global Cancer Demographics
Exhibit 42: Cancer Incidents (2006, 2011 & 2020): Estimates and Projections for Global Cancer
Incidents in Million/Year with Mortality Percentage (*Graphical Representation Included*).

Alzheimer's

Dermatology

Cosmetic Dermatology
Angiogenesis in Dermatology
Angiogenesis Inhibitor
Angiogenesis Stimulating Drugs

Psoriasis

Role of Angiogenesis in Psoriasis
Rosacea
MoA of Photoaging in Rosacea Pathogenesis

Ophthalmology

Age Related Macular Degeneration
Advanced stage of vision loss
Causes
Characteristics of the disorder
Detection process of the Disorder
Medication
Precautionary measure
Types of AMD.
Non-Neo-vascular (dry) AMD
Neo-vascular (wet) AMD
Other Turmoil Based on Angiogenesis.
Rubeosis Iridis
Neovascularization.
Neovascularization in Association with Angiogenesis

Rheumatology

Rheumatoid Arthritis
Angiogenesis in Rheumatoid Arthritis – Pathogenic and Therapeutic Implications
Skin Related Ailments
Deficient Angiogenesis in Skin Diseases

Osteoarthritis (OA), Angiogenesis and Inflammation

Other

Inflammatory Diseases

Growth of New Blood Vessels in Inflammation
Cause of joint swelling due to inflammation

Endometriosis

Symptoms of the Disease

3.2 Remedy of Diseases with Angiogenesis Stimulators

Wound Care – Role of Angiogenesis

Soluble Factors Responsible for Wound Angiogenesis

Diabetic Foot Ulcers

Angiogenesis in Cardiovascular Disorders

Growth Trends – Global Market for Angiogenesis Therapeutic Products for

Cardiovascular Disorders

Exhibit 43: Global Market for Angiogenesis Therapeutic Products for Cardiovascular Disorders:

Geographic Regions (United States, Asia-Pacific and Europe) Ranked by Projected CAGR for 2005 through 2012 (*Graphical Representation Included*)

Ischemia

Role of ASK 1 in Angiogenesis during Ischemia

Role of NGF in Neo-Vascularization during Ischemic Conditions

Congestive Heart Failure

Root of CHF

Detection of CHF

Treatment of CHF

Role of Angiogenesis in CHF

Coronary Artery Disease

Angina

Heart Attack

Heart Failures

Arrhythmias

Symptoms Identified for CAD

Role of Angiogenesis in CAD Treatment

Peripheral Vascular Disease

Angiogenic Therapy for the Treatment of PVD

Peripheral Artery Disease

Therapeutic Angiogenesis in PAD

Myocardial Infarction

Treatment of Myocardial Infarction Using Non-Invasive Imaging of Myocardial Angiogenesis

IV. MARKET DYNAMICS

1. Market Overview

Global Market Analysis

Exhibit 44 Angiogenesis Therapeutic Products (2005-2012) – Global Market Analysis (Current & Future) by Geographic Region for United States, Europe, Asia-Pacific and Rest of World in US\$ Million (*Graphical Representation Included*)

Exhibit 45 Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Global Market Value by Geographic Region for United States, Europe, Asia-Pacific and Rest of World (*Graphical Representation Included*)

2. Major Companies in Angiogenesis Industry

Abbott Laboratories (USA)

Adnexus Therapeutics, Inc. (USA)

Aeterna Zentaris, Inc. (Canada)

Alcon, Inc. (USA)

Amgen, Inc. (USA).

Angiotech Pharmaceuticals, Inc. (Canada)

Ångstrom Pharmaceuticals, Inc. (USA).

Antisoma plc (UK)

Astrazeneca plc (UK)
Bayer Healthcare AG (Germany)
Callisto Pharmaceuticals, Inc. (USA)
Cardium Therapeutics, Inc. (USA)
Celgene Corporation (USA)
Chugai Pharmaceutical Co., Ltd. (Japan)
Collagenex Pharmaceuticals, Inc. (USA).
Eisai, Inc. (USA)
Entremed, Inc. (USA)
F.Hoffmann-La Roche Ltd. (Switzerland)
Genaera Corporation (USA)
Genentech, Inc. (USA)
Genvec, Inc. (USA)
Genzyme Corporation (USA)
Human Genome Sciences, Inc. (USA)
Imclone Systems, Inc. (USA)
Intradigm Corporation (USA)
Merck & Co., Inc. (USA)
Merck KGaA (Germany)
Novartis AG (Switzerland)
OSI Pharmaceuticals, Inc. (USA)
Oxigene, Inc. (USA)
Pfizer, Inc. (USA)
Progen Industries Ltd. (Australia)
TAP Pharmaceutical Products, Inc. (USA)
UCB SA (Belgium)
More.....

3. Major Activities in Angiogenesis Industry

4. Regional Market Analysis

A. The United States

Market Analysis

Cancer Incidents in the United States

Exhibit 46: Cancer Incidents and Percentage of Deaths in the United States in 2005 and 2006

Exhibit 47: US Cancer Incidents (2006): No. of Cases by Type of Cancer – Prostate, Breast, Lung, Colorectal and Other (*Graphical Representation Included*)

US Market for Interventional Peripheral Vascular Products

Exhibit 48: Interventional Peripheral Vascular Products (2004 & 2009) – The US Market Analysis in US\$ Million

Analysis by Type of Angiogenesis Modulators

Exhibit 49: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 50: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

Analysis by Disease Area

Exhibit 51: Angiogenesis Therapeutic Products (2005-2012) – United States Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US\$ Million (*Graphical Representation Included*)

Exhibit 52: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United States Market Value by Disease Area for Cancer, Cardiovascular and Other

Exhibit 53: List of Major Companies in the United States.

B. Europe

Market Analysis

Exhibit 54: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

Analysis by Geographic Region

Exhibit 55: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Geographic Region for Germany, United Kingdom, France, Switzerland, and Rest of Europe in US\$ Million (*Graphical Representation Included*)

Exhibit 56: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Geographic Region for Germany, United Kingdom, France Switzerland, and Rest of Europe

Analysis by Type of Angiogenesis Modulators

Exhibit 57: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*).

Exhibit 58: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

Analysis by Disease Area

Exhibit 59: Angiogenesis Therapeutic Products (2005-2012) – European Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US\$ Million (*Graphical Representation Included*)

Exhibit 60: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of European Market Value by Disease Area for Cancer, Cardiovascular and Other

Exhibit 61 List of Major Companies in Europe

European Angiogenesis Modulators Market by Country

B1. Germany

German Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 62: Angiogenesis Therapeutic Products (2005-2012) – German Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 63: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of German Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

B2. The United Kingdom

UK Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 64: Angiogenesis Therapeutic Products (2005-2012) – United Kingdom Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 65: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of United Kingdom Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

B3. France

French Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 66: Angiogenesis Therapeutic Products (2005-2012) – French Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 67: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of French Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

B4. Switzerland

Swiss Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 68: Angiogenesis Therapeutic Products (2005-2012) – Swiss Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*).

Exhibit 69: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Swiss Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

B5. Rest of Europe

Rest of Europe Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 70: Angiogenesis Therapeutic Products (2005-2012) – Rest of Europe Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 71: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of Europe Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

C. Asia-Pacific

Market Analysis

Exhibit 72: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

Analysis by Geographic Region

Exhibit 73: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Geographic Region for Japan and Rest of Asia-Pacific in US\$ Million (*Graphical Representation Included*)

Exhibit 74: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Geographic Region for Japan and Rest of Asia-Pacific (*Graphical Representation Included*)

Analysis by Angiogenesis

Exhibit 75: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 76: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

Analysis by Disease Area

Exhibit 77: Angiogenesis Therapeutic Products (2005-2012) – Asia-Pacific Market Analysis

(Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US\$ Million (*Graphical Representation Included*)

Exhibit 78: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Asia-Pacific Market Value by Disease Area for Cancer, Cardiovascular and Other

Exhibit 79: List of Major Companies in Asia-Pacific

Asia-Pacific Angiogenesis Modulators Market by Country

C1. Japan

Japanese Market Analysis

Analysis by Angiogenesis Modulators

Exhibit 80: Angiogenesis Therapeutic Products (2005-2012) – Japanese Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*).

Exhibit 81: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Japanese Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

C2. Rest of Asia-Pacific

Rest of Asia-Pacific Market Analysis

Analysis by Type of Angiogenesis Modulators

Exhibit 82: Angiogenesis Therapeutic Products (2005-2012) – Rest of Asia-Pacific Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 83: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of Asia-Pacific Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

D. Rest of World

Market Analysis

Exhibit 84: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) in US\$ Million (*Graphical Representation Included*)

Analysis by Geographic Region

Exhibit 85: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Geographic Region for Latin America and Other in US\$ Million (*Graphical Representation Included*)

Exhibit 86: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Geographic Region for Latin America and Other (*Graphical Representation Included*)

Analysis by Angiogenesis

Exhibit 87: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*).

Exhibit 88: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown

of Rest of World Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

Analysis by Disease Area

Exhibit 89: Angiogenesis Therapeutic Products (2005-2012) – Rest of World Market Analysis (Current & Future) by Disease Area for Cancer, Cardiovascular and Other in US\$ Million (*Graphical Representation Included*)

Exhibit 90: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Rest of World Market Value by Disease Area for Cancer, Cardiovascular and Other

Rest of World Angiogenesis Market by Region

D1. Latin America

Latin American Market Analysis

Analysis by Angiogenesis Modulators

Exhibit 91: Angiogenesis Therapeutic Products (2005-2012) – Latin America Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*).

Exhibit 92: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Latin America Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*)

D2. Rest of World (Excluding Latin America)

Other Region in Rest of World's Market Analysis

Analysis by Angiogenesis Modulators

Exhibit 93: Angiogenesis Therapeutic Products (2005-2012) – Other Region of Rest of World Market Analysis (Current & Future) by Angiogenesis Modulators for Inhibitors and Stimulators in US\$ Million (*Graphical Representation Included*)

Exhibit 94: Angiogenesis Therapeutic Products (2006, 2009 and 2012) – Percentage Breakdown of Other Region of Rest of World Market Value by Angiogenesis Modulators for Inhibitors and Stimulators (*Graphical Representation Included*).

Exhibit 95: List of Major Companies in Rest of World (Excluding Latin America)

5. Angiogenesis Modulators - The Industry Outlook

V. CORPORATE DIRECTORY